Chinese Luxury Car Brand, HONGQI, Has Made Its Presence Known at the Goodwood Festival of Speed, Showcasing Its Global Strength
HONGQI, the Chinese luxury car brand, will become the official partner of the 2024 Goodwood Festival of Speed and will make its appearance at the event from July 11th to 14th. HONGQI will take the stage alongside a distinguished line of global luxury cars, showcasing its exceptional strength and unique charm as the top luxury car brand in China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711264873/en/
Chinese luxury car brand, HONGQI, has made its presence known at the Goodwood Festival of Speed, showcasing its global strength (Photo: Business Wire)
Established in 1958, HONGQI represents the development and achievements of China's automotive industry. Today, HONGQI holds an important position in China's high-end luxury car market and is accelerating its global market strategy. Its distribution network already covers 28 countries and regions worldwide.
HONGQI will showcase five star models at the Goodwood Festival of Speed, including the HONGQI Guoya, E-HS9, H9, as well as the upcoming EH7 and EHS7, which will soon be available in European countries such as Norway, German, France and Denmark. This will be an exciting intersection between Chinese and global automotive cultures, presenting an excellent opportunity for Hongqi to showcase the strength of China's automotive industry.
As a high-end Chinese automotive brand, HONGQI carries the deep history and technological heritage of China's automotive industry. At the Goodwood Festival of Speed, HONGQI will demonstrate the exceptional quality of Chinese luxury cars.
HONGQI is accelerating the development of key technologies and enhancing its international market competitiveness. At the same time, HONGQI is showcasing its brand's high-end image and conveying the luxurious lifestyle associated with HONGQI. Following the Goodwood Festival of Speed, HONGQI will engage in cross-industry collaborations with multiple top international brands, collectively transforming "Orientation luxury" into "the world's new luxury," setting a new benchmark for Chinese brands in the global high-end automotive market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711264873/en/
Contacts
Lin Ding
China FAW Group Import & Export Co., Ltd
Website: https://www.hongqi-auto.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.hongqi-aut
o.com&esheet=54093260&newsitemid=20240711264873&lan=en-US&anchor=https%3A%2F%2Fw
ww.hongqi-auto.com&index=1&md5=183732b8dbbf7bbe765c9b4ee1c9ea97
Email: dinglin7@faw.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom